7 Oversold Pharma Stocks to Buy Now

2. Bausch Health Companies Inc. (NYSE:BHC)

Relative Strength Index: 51.76

Price Target Upside: 27.59%

Bausch Health Companies Inc. (NYSE:BHC) is one of the most oversold stocks.

TheFly reported on February 19 that Bank of America raised its price target for Bausch + Lomb (BLCO) to $15 from $13 and kept an Underperform rating. The firm pointed out that Bausch + Lomb’s fourth-quarter revenue was 2% more than anticipated and that the company expects the contact lens market to increase by at least 4.5% in 2026. The assessment indicates continued concern regarding BHC’s complete separation, notwithstanding these positives.

Bausch Health Companies Inc. (NYSE:BHC) released its financial results for the fourth quarter and the entire year 2025 on February 18. The company reported consolidated sales of $10.27 billion for the entire year, a 7% increase year over year, and $2.80 billion for the fourth quarter, up 9% from the same period in 2024.

The full-year GAAP net income was $157 million, but the fourth-quarter GAAP statistics revealed a net loss of $112 million. Strong demand for Xifaxan helped the Salix sector continue to drive growth, generating $693 million in Q4 revenue. These outcomes highlight BHC’s continuous operational performance and the beneficial input from its main business divisions.

Bausch Health Companies Inc. (NYSE:BHC) is a global pharmaceutical company specializing in eye care, dermatology, gastrointestinal, and branded generic medicines, providing prescription and over-the-counter products to improve patient health worldwide.